Clinical Utilities
Antineutrophil cytoplasmic autoantibodies (ANCA) are a serological marker associated with vasculitis and glomerulonephritis. Specifically, ANCA have been found (at frequencies ranging from 70% to 90%) in patients with active Wegener's granulomatosis, microscopic polyarteritis nodosa, and idiopathic crescentic glomerulonephritis (with manifestations ranging from kidney-limited disease to extrarenal systemic disease, including pulmonary-renal syndromes). Glomerular lesions in patients with ANCA-associated systemic vasculitis or renal- limited disease are virtually identical. Normal controls are negative for ANCA and <10% of patients with other renal diseases are positive. ANCA may be directly involved in the pathogenesis of the vascular injury that causes the clinical manifestations in ANCA-associated disease.

CPT Codes
86039, 86021x3

The CPT codes provided are based on AMA guidelines
and are for informational purposes only. CPT coding is the
sole responsibility of the billing party. Please direct any questions
regarding coding to the payer being billed.

Reference Range
ANCA Total Autoantibodies:          < 1:20 
Myeloperoxidase Autoantibodies: < 9.0 U/mL  
Proteinase-3 Autoantibodies:        < 3.5 U/mL 
Antinuclear Antibodies (ANA)        <7.5 IU/mL  

Component Information

Name		ANCA TOTAL ANTIBODIES
Method		IFA
CPT Code		86021
Units		<1:20 FIU
Ref Range
Reflex Reason

Name		ANCA PATTERN
Method		IFA
CPT Code
Units
Ref Range		Not Detected
Reflex Reason

Name		PROTEINASE-3 AUTOANTIBODIES
Method		EIA
CPT Code		86021
Units		<3.5 U/mL
Ref Range
Reflex Reason

Name		ANTINUCLEAR ANTIBODIES (ANA)
Method		IFA/IMAGE
CPT Code		86039
Units		IFA/IMAGE
Ref Range		Less than 7.5
Reflex Reason

Name		ANA PATTERN
Method		IFA
CPT Code
Units		IFA
Ref Range
Reflex Reason

Name		MYELOPEROXIDASE AUTOANTIOBODIES
Method		EIA
CPT Code		86021
Units		<9.0 U/mL
Ref Range
Reflex Reason

Collection Notes

Additional Comments
Specialty recommends simultaneous testing for Glomerular Basement Membrane IgG Autoabs, #1136 if clinically indicated. See PAN-ANCA(tm) PLUS, #1868, the method of choice for ANCA. See also Rapidly Progressive Glomerulonephritis Evaluation, #1726.